Clinical Trials Logo

Gastrooesophageal Cancer clinical trials

View clinical trials related to Gastrooesophageal Cancer.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05071053 Active, not recruiting - Clinical trials for Gastrooesophageal Cancer

Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab in Pretreated Participants With Gastric Cancer

CARMEN-GC01
Start date: November 16, 2021
Phase: Phase 2
Study type: Interventional

Primary Objectives: Part 1: to confirm the recommended tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma population Part 2: to assess the antitumor activity of tusamitamab ravtansine loading dose Q2W in combination with ramucirumab in advanced gastric or GEJ adenocarcinoma Secondary Objectives: - To assess safety - To assess durability - To assess progression-free survival (PFS) - To assess the disease control rate (DCR) - To assess the pharmacokinetics (PK) - To assess the immunogenicity